Walgreens Boots Alliance goes private: What Sycamore’s $23.7bn deal signals for pharmacy retail’s next chapter

Why did Sycamore take Walgreens Boots Alliance private—and what’s at stake for the global pharmacy giant?

In what could mark one of the most consequential retail healthcare buyouts of the decade, Sycamore Partners has completed its acquisition of Walgreens Boots Alliance, Inc. (NASDAQ: WBA), officially taking the 311,000-employee company private. The final cash-out price for shareholders was $11.45 per share, supplemented by a unique instrument: a non-transferable right to receive up to an additional $3.00 in cash per share tied to the future monetization of Walgreens’ investment in VillageMD, Summit Health, and CityMD.

The transaction, initially announced in March 2025, valued Walgreens Boots Alliance at up to $23.7 billion, including debt and settlement-related adjustments. While shareholders receive immediate liquidity, the structure of the deal—especially the Divested Asset Proceed Rights (DAP Rights)—signals a broader, high-stakes play on asset divestiture and healthcare platform value realization over time.

How does Sycamore’s retail DNA align with Walgreens’ turnaround ambitions in a disrupted health ecosystem?

Sycamore, best known for its retail and consumer-focused portfolio including Staples and Belk, now enters the healthcare-pharmacy integration space via Walgreens’ extensive footprint of 12,500 stores and its affiliated health services. By splitting Walgreens, Boots UK, VillageMD, CareCentrix, and Shields Health Solutions into standalone private entities, Sycamore is betting that decentralization will drive turnaround flexibility, operational speed, and customer-centric reinvention.

Stefan Kaluzny, Sycamore’s Managing Director, framed the acquisition as a partnership with both leadership and legacy. He emphasized that each of the businesses—whether retail pharmacy or health services—will deepen their customer relationships under private ownership and dedicated strategies.

This marks a dramatic shift away from the conglomerate-style integration that defined Walgreens Boots Alliance under public ownership, especially during its acquisition-heavy era between 2014 and 2020. The new model embraces fragmentation with focused execution—a strategy in line with private equity turnaround playbooks.

What role does Stefano Pessina play in the deal—and what does his reinvestment signal?

The presence—and financial commitment—of Walgreens’ longtime Executive Chairman Stefano Pessina is central to the deal’s credibility. Pessina and his family, who collectively hold around 17% of WBA shares, not only voted in favor of the transaction but also reinvested their entire cash payout into the new Sycamore-controlled entity. They also made an incremental cash infusion, maintaining long-term alignment with the privatized businesses.

Although Pessina recused himself from WBA’s board deliberations, his behind-the-scenes engagement was instrumental in facilitating Sycamore’s financing structure. His vote of confidence also plays a symbolic role in reassuring suppliers, employees, and health partners that this is not just a financial reshuffling—but a strategic reset.

What happens to VillageMD and the $3.4B Walgreens loan tied to its future sale?

The most complex—and potentially lucrative—component of the deal is the Divested Asset Proceed Right (DAP Right), which ties part of shareholder value to future outcomes.

At the time of the transaction, Walgreens had a $3.4 billion loan to VillageMD, accruing a high-yield 19% PIK (payment-in-kind) interest rate. After closing, a newly formed Divested Assets Committee—comprising representatives from Sycamore, Pessina, and pre-closing WBA board members—will oversee the process of selling VillageMD and associated brands.

WBA shareholders will receive 70% of the net proceeds from any sale (up to $3 per share) until the full loan amount is recovered. But this isn’t a guaranteed payout. If no buyer emerges or the sale fetches less than projected, the DAP Rights could expire worthless.

With urgent care and primary care consolidations facing funding pressures—and VillageMD already facing financial strain—analysts say a successful monetization could take several quarters or longer, injecting uncertainty into what is otherwise a clean break from public markets.

How did institutional shareholders react—and what were the deal’s premium mechanics?

The deal delivered a 29% premium over Walgreens’ share price on December 9, 2024—the day before rumors surfaced—and up to a 63% premium when factoring in the full $3 per share upside from VillageMD’s potential sale.

Still, institutional sentiment has been mixed. Some funds welcomed the immediate cash component as a much-needed exit from a chronically underperforming stock. Others questioned the opacity of the DAP Right structure and the lack of a transferable vehicle to manage post-close value realization.

Sycamore was required to secure a majority of unaffiliated shareholder votes, excluding Pessina’s stake, during the approval process. That threshold was met, indicating cautious optimism but also underlying fatigue with Walgreens’ stalled public market performance.

Why did Walgreens Boots Alliance pursue a private exit—and what does it signal about sector headwinds?

Outgoing CEO Tim Wentworth attributed the decision to go private to the operational and capital flexibility required to deliver on Walgreens’ healthcare-led turnaround strategy.

As Wentworth noted during the announcement phase, “meaningful value creation will take time, focus and change that is better managed as a private company.” From shifting reimbursement models in pharmacy to shrinking foot traffic and rising competition from Amazon Pharmacy, CVS Health, and regional players, WBA faced pressures that public market timelines and reporting cycles weren’t suited to absorb.

With Sycamore’s backing, Walgreens now joins a growing list of legacy retail-healthcare hybrids that are pivoting toward strategic reinvention under private ownership. The expectation is that these standalone businesses—freed from quarterly earnings scrutiny—can now pursue deeper structural change.

What’s the outlook for Walgreens’ global operations—including Boots UK and Latin America?

Although the deal structure separates Walgreens, Boots, CareCentrix, Shields Health Solutions, and VillageMD into distinct private companies, the operating philosophy will remain tied to community healthcare access, consumer loyalty, and localized footprint management.

Boots UK, which has long been a point of speculation for divestiture or IPO, will remain part of Sycamore’s private portfolio, though future asset-level monetization may be back on the table.

In Latin America, where Walgreens operates through Benavides and other brands, analysts expect portfolio optimization but not full-scale exits. The overriding strategy appears to be “local focus with financial engineering,” a hallmark of Sycamore’s past playbooks.

Is this Sycamore’s boldest pharmacy retail gamble yet—or a well-calculated platform reboot?

With Walgreens Boots Alliance now officially delisted from Nasdaq and operating under a private structure, the market will watch closely how Sycamore balances short-term cost efficiencies with long-term brand and healthcare ecosystem value.

This deal isn’t just a turnaround bet—it’s a test of whether retail-first private equity can reshape a global healthcare-facing enterprise into a profitable, patient-centric, tech-enabled platform. And with over 311,000 employees, thousands of retail locations, and a top-three position in pharmacy dispensing, Walgreens’ next chapter may be as influential in the private arena as it was in public.

Whether the DAP Rights ultimately pay out or not, one thing is certain: Sycamore just made one of the most high-profile, high-leverage entries into retail healthcare. And it intends to win.